SCHEMBL6577083

SCHEMBL6577083

CN(C)[C@H](c1ccccc1)[C@@H](O)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 7/20 0.70
KDM4E B2RXH2 2/20 0.63
ALDH1A1 P00352 2/20 0.63
ADRA2C P18825 2/20 0.50
SLC6A2 P23975 2/20 0.50
SLC6A4 P31645 2/20 0.50
ADRA2A P08913 1/20 0.50
LMNA P02545 1/20 0.50
HIF1A Q16665 1/20 0.50
SLC6A3 Q01959 1/20 0.50
CYP2C9 P11712 2/20 0.47
CHRM2 P08172 1/20 0.47
ADRA1A P35348 1/20 0.47
RGS12 O14924 1/20 0.47
GLA P06280 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19658277 1.00 AOC3 (0.70) AOC3KDM4EALDH1A1ADRA2CSLC6A2
SCHEMBL19658276 1.00 AOC3 (0.70) AOC3KDM4EALDH1A1ADRA2CSLC6A2
SCHEMBL11353001 1.00 AOC3 (0.70) AOC3KDM4EALDH1A1ADRA2CSLC6A2
SCHEMBL21340477 1.00 AOC3 (0.70) AOC3KDM4EALDH1A1ADRA2CSLC6A2
SCHEMBL19658275 1.00 AOC3 (0.70) AOC3KDM4EALDH1A1ADRA2CSLC6A2
SCHEMBL6580072 1.00 AOC3 (0.70) AOC3KDM4EALDH1A1ADRA2CSLC6A2
SCHEMBL7586902 0.83 HTR2A (0.52) AOC3KDM4EALDH1A1SLC6A2SLC6A4
SCHEMBL6742085 0.83 AOC3 (1.00) AOC3KDM4EALDH1A1ADRA2CSLC6A2
SCHEMBL15139983 0.83 AOC3 (1.00) AOC3KDM4EALDH1A1ADRA2CSLC6A2
SCHEMBL6742087 0.83 AOC3 (1.00) AOC3KDM4EALDH1A1ADRA2CSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210179536-A1 METHOD OF SYNTHESIZING (1R,2R)-NITROALCOHOL COMPOUND SICHUAN UNIVERSITY (CN) 2021-06-17 US claimed
CN-110878024-A Synthesis method of (1R,2R) -nitroalcohol compound 四川大学 2020-03-13 CN claimed
US-11623913-B2 Method of synthesizing (1R,2R)-nitroalcohol compound SICHUAN UNIVERSITY (CN) 2023-04-11 US disclosed
US-20210179536-A1 METHOD OF SYNTHESIZING (1R,2R)-NITROALCOHOL COMPOUND SICHUAN UNIVERSITY (CN) 2021-06-17 US disclosed
CN-110878024-B Synthesis method of (1R,2R) -nitroalcohol compound 四川大学 2021-02-26 CN disclosed
CN-110878024-A Synthesis method of (1R,2R) -nitroalcohol compound 四川大学 2020-03-13 CN disclosed
US-7692019-B2 Methods for the stereoselective synthesis of substituted piperidines SEPRACOR INC. (US) 2010-04-06 US disclosed
US-20040236118-A1 Pyrrolidine derivatives and method of synthesizing these EIZAI CO., LTD (JP) 2004-11-25 US disclosed
EP-1413574-A1 PYRROLIDINE DERIVATIVES AND METHOD OF SYNTHESIZING THESE Eizai Co., Ltd. (JP) 2004-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236118-A1 Pyrrolidine derivatives and method of synthesizing these ADH1C, ADH5, ADH1A AOC3 1294/4885KDM4E 1456/4885ALDH1A1 145/4885
US-20210179536-A1 METHOD OF SYNTHESIZING (1R,2R)-NITROALCOHOL COMPOUND ADH1C, ADH1A, CBR1 AOC3 23/4885KDM4E 4110/4885ALDH1A1 18/4885
US-11623913-B2 Method of synthesizing (1R,2R)-nitroalcohol compound ADH1C, ADH1A, CBR1 AOC3 23/4885KDM4E 4110/4885ALDH1A1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.